Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials
Topic
IL-17 Inhibitor
Secukinumab, ixekizumab, bimekizumab, IL-17 pathway positioning, payer access, and immunology competition.